Read + Share
Furuya K, Nakajima M, Tsunedomi R, Nakagami Y, et al. High serum proteinase-3 levels predict poor progression-free survival and lower
efficacy of bevacizumab in metastatic colorectal cancer. BMC Cancer 2024;24:165.
PMID: 38308214
|
 |
|
Furuya K, Nakajima M, Tsunedomi R, Nakagami Y, et al. High serum proteinase-3 levels predict poor progression-free survival and lower
efficacy of bevacizumab in metastatic colorectal cancer. BMC Cancer 2024;24:165.
PMID: 38308214
|
|
|
|